JP7187488B2 - 固定用量製剤 - Google Patents

固定用量製剤 Download PDF

Info

Publication number
JP7187488B2
JP7187488B2 JP2019565302A JP2019565302A JP7187488B2 JP 7187488 B2 JP7187488 B2 JP 7187488B2 JP 2019565302 A JP2019565302 A JP 2019565302A JP 2019565302 A JP2019565302 A JP 2019565302A JP 7187488 B2 JP7187488 B2 JP 7187488B2
Authority
JP
Japan
Prior art keywords
ezetimibe
bempedoic acid
tablet
amount
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521763A (ja
Inventor
アブデルナセール，モハメド
ピルガオンカル，プラティバ，エス．
エス． ガンディー，アニルクマール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of JP2020521763A publication Critical patent/JP2020521763A/ja
Priority to JP2022191728A priority Critical patent/JP7561814B2/ja
Application granted granted Critical
Publication of JP7187488B2 publication Critical patent/JP7187488B2/ja
Priority to JP2024164776A priority patent/JP2024178341A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019565302A 2017-05-26 2018-05-25 固定用量製剤 Active JP7187488B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022191728A JP7561814B2 (ja) 2017-05-26 2022-11-30 固定用量製剤
JP2024164776A JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511889P 2017-05-26 2017-05-26
US62/511,889 2017-05-26
US15/859,279 US20180338922A1 (en) 2017-05-26 2017-12-29 Fixed dose formulations
US15/859,279 2017-12-29
PCT/US2018/034646 WO2018218147A1 (en) 2017-05-26 2018-05-25 Fixed dose formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022191728A Division JP7561814B2 (ja) 2017-05-26 2022-11-30 固定用量製剤

Publications (2)

Publication Number Publication Date
JP2020521763A JP2020521763A (ja) 2020-07-27
JP7187488B2 true JP7187488B2 (ja) 2022-12-12

Family

ID=62621055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019565302A Active JP7187488B2 (ja) 2017-05-26 2018-05-25 固定用量製剤
JP2022191728A Active JP7561814B2 (ja) 2017-05-26 2022-11-30 固定用量製剤
JP2024164776A Pending JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022191728A Active JP7561814B2 (ja) 2017-05-26 2022-11-30 固定用量製剤
JP2024164776A Pending JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Country Status (15)

Country Link
US (2) US20180338922A1 (https=)
EP (1) EP3630070A1 (https=)
JP (3) JP7187488B2 (https=)
KR (3) KR20250109242A (https=)
CN (1) CN110996914A (https=)
AU (2) AU2018272040A1 (https=)
BR (1) BR112019024747A2 (https=)
CA (1) CA3064895A1 (https=)
CL (1) CL2019003437A1 (https=)
IL (2) IL270866B2 (https=)
MX (2) MX2019014122A (https=)
PH (1) PH12019502782A1 (https=)
TW (1) TWI798228B (https=)
UA (1) UA126451C2 (https=)
WO (1) WO2018218147A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
AU2019221765A1 (en) * 2018-02-16 2020-09-10 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
US12516013B2 (en) 2019-12-06 2026-01-06 Synthon B.V. Crystalline forms of sodium salt of Bempedoic acid
CN115379861A (zh) * 2020-04-10 2022-11-22 日本瓦姆&珀巴尔株式会社 缓释性主剂
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
US20250134841A1 (en) 2021-09-13 2025-05-01 Synthon B.V. Pharmaceutical composition of bempedoic acid
CA3256768A1 (en) 2022-05-09 2023-11-16 Renata Pharmaceutical (Ireland) Ltd PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
JP2024116544A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機
JP2024116545A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
JP4438268B2 (ja) 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
ES2382773T3 (es) * 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
CA2755274C (en) * 2009-03-13 2017-02-28 Sahoe Kakuda Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
PT2459175T (pt) * 2009-07-28 2018-02-07 Egyt Gyogyszervegyeszeti Gyar Novo processo de granulação e o granulado assim preparado
CN101926756B (zh) * 2010-08-12 2012-01-18 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
MX378845B (es) * 2014-01-21 2025-03-10 Bpsi Holdings Llc Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Also Published As

Publication number Publication date
JP7561814B2 (ja) 2024-10-04
RU2019142143A (ru) 2021-06-28
TW201900154A (zh) 2019-01-01
UA126451C2 (uk) 2022-10-05
TWI798228B (zh) 2023-04-11
AU2018272040A1 (en) 2019-12-19
JP2024178341A (ja) 2024-12-24
IL270866A (en) 2020-01-30
KR102830720B1 (ko) 2025-07-08
KR102698987B1 (ko) 2024-08-28
US20180338922A1 (en) 2018-11-29
MX2023006541A (es) 2023-06-16
JP2023022224A (ja) 2023-02-14
MX2019014122A (es) 2020-02-07
IL318957A (en) 2025-04-01
KR20250109242A (ko) 2025-07-16
PH12019502782A1 (en) 2020-10-26
KR20200032044A (ko) 2020-03-25
KR20240130156A (ko) 2024-08-28
RU2019142143A3 (https=) 2021-07-19
IL270866B2 (en) 2025-07-01
AU2024204369A1 (en) 2024-07-11
WO2018218147A1 (en) 2018-11-29
EP3630070A1 (en) 2020-04-08
BR112019024747A2 (pt) 2020-06-09
US20220249380A1 (en) 2022-08-11
IL270866B1 (en) 2025-03-01
CL2019003437A1 (es) 2020-07-10
JP2020521763A (ja) 2020-07-27
TW202400126A (zh) 2024-01-01
CN110996914A (zh) 2020-04-10
CA3064895A1 (en) 2018-11-29
AU2024204369B2 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
JP7187488B2 (ja) 固定用量製剤
KR101380088B1 (ko) 약학 조성물
US20230414578A1 (en) Pharmaceutical composition
EP4221704B1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
CA3094115A1 (en) Pharmaceutical composition comprising meta arsenite and method of manufacture
EA030982B1 (ru) Твердая галеновая форма с высоким содержанием фексофенадина и способ ее получения
KR20220112746A (ko) 치료 제형 및 이의 용도
CN100479808C (zh) 贝特类片剂及其制备方法
TWI921644B (zh) 固定劑量調配物
RU2810163C2 (ru) Составы в фиксированных дозах
HK40020442A (en) Fixed dose formulations
WO2019101151A1 (zh) 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物
WO2024183471A1 (zh) 片剂及其制备方法与用途
CN120189417A (zh) 莫非赛定利托那韦的复方制剂及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221130

R150 Certificate of patent or registration of utility model

Ref document number: 7187488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250